Oral difelikefalin reduces moderate to severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis
Journal of Allergy and Clinical Immunology · 2023-10 · 152 (4) · 916-926
DOI: 10.1016/j.jaci.2023.06.023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2023-10. Verfasst von Emma Guttman-Yassky und 14 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, New York, NY. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cidara Therapeutics.
Abstract (Originalsprache)
BACKGROUND: Pruritus is the most common and burdensome symptom of atopic dermatitis (AD). Pruritus-targeted treatments in AD are lacking, particularly for patients with milder skin disease. OBJECTIVE: We sought to evaluate the impact of the selective κ-opioid receptor agonist difelikefalin (DFK) on pruritus intensity and pruritus- and immune-related biomarkers in subjects with moderate to severe AD-related pruritus. METHODS: A phase 2 clinical trial investigated the efficacy and safety of oral DFK 0.25, 0.5, and 1.0 mg in subjects with moderate to severe AD-related pruritus. A biomarker substudy evaluated the effects of DFK on the expression of pruritus, TH2-associated genes, and skin barrier-related genes. RESULTS: In the clinical trial (N = 401), all DFK doses reduced itch versus placebo; however, the results were not statistically significant at week 12. In a subgroup of subjects in the trial with mild to moderate skin inflammation and moderate to severe itch (itch-dominant AD phenotype), DFK reduced itch at week 12 versus placebo. In the biomarker substudy, DFK downregulated the expression of key pruritus-related genes (eg, IL-31 and TRPV1) and the AD phenotype (eg, CCL17). Gene set variation analysis confirmed that DFK, but not placebo, downregulated pruritus-related genes and TH2 pathways. DFK improved skin barrier integrity markers and upregulated the expression of claudins and lipid metabolism-associated genes (eg, SEC14L6, ELOVL3, CYP1A2, and AKR1D1). CONCLUSIONS: DFK treatment reduced itch in subjects with moderate to severe AD-related pruritus, particularly those with an "itch-dominant" AD phenotype, and had an impact on the expression of pruritus, TH2-associated genes, and skin barrier-related genes. DFK is a promising therapy for AD-related pruritus; further clinical studies are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Icahn School of Medicine at Mount Sinai, New York, NY.
- Cara Therapeutics, Inc, Stamford, Conn.
- Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: Brian.Kim3@mountsinai.org.
Förderung
- Cidara Therapeutics
Zitieren
APA
Guttman-Yassky, E., Facheris, P., Da Rosa, J. C., Rothenberg-Lausell, C., Del Duca, E., David, E., Estrada, Y., Liu, Y., Bose, S., Chowdhury, M., Munera, C., Goncalves, J., Nograles, K., Kim, B. S., & Lebwohl, M. (2023). Oral difelikefalin reduces moderate to severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis. Journal of Allergy and Clinical Immunology, 152(4), 916-926. https://doi.org/10.1016/j.jaci.2023.06.023
Vancouver
Guttman-Yassky E, Facheris P, Da Rosa JC, Rothenberg-Lausell C, Del Duca E, David E, et al. Oral difelikefalin reduces moderate to severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis. Journal of Allergy and Clinical Immunology. 2023;152(4):916-926. doi:10.1016/j.jaci.2023.06.023
BibTeX
@article{GuttmanYassky2023,
author = {Guttman-Yassky, Emma and Facheris, Paola and Da Rosa, Joel Correa and Rothenberg-Lausell, Camille and Del Duca, Ester and David, Eden and Estrada, Yeriel and Liu, Ying and Bose, Swaroop and Chowdhury, Mashkura and Munera, Catherine and Goncalves, Joana and Nograles, Kristine and Kim, Brian S and Lebwohl, Mark},
title = {Oral difelikefalin reduces moderate to severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis},
journal = {Journal of Allergy and Clinical Immunology},
year = {2023},
volume = {152},
number = {4},
pages = {916--926},
doi = {10.1016/j.jaci.2023.06.023}
}
EUVIMED